.
R&D
Research & Development
Kolon Pharmaceuticals is dedicated to innovating and creating value through relentless research and development.
Orthotopic Animal Model
Aids both independent & joint drug development via a global standard of orthotopic animal model services
Simulates the human body environment by injecting cancer cells into corresponding target organs in mice
Aims to create a model mirroring actual patient tumor tissues by interacting with the microscopic tumor environments.
Orthotopic Animal Model
Comparison Items
Orthotopic Animal Model
Subcutaneous Tissue
Spread of generated area to other organs
Same organ
Low
Clinical replication success rate
High
X
Propagation to the identical organ
O
X
Interaction with adjacent tissues
O
In vivo Anti-Cancer Effect
Unlike the ectopic animal model, cell inhibitory activity and apoptosis efficacy were confirmed in various solid cancer cell lines.
For the ectopic animal model, drug candidate B demonstrated the most significant decrease in tumor volume. However, in the orthotopic animal model, drug candidate A achieved the best results out of the three candidates.
Pancreatic Cancer Orthotopic Model Test Results by PLATBIO
Ectopic Animal Model
Orthotopic Animal Model
Improved clinical trial success rate
Enhanced protocol completeness
Indication expansion
Fine-tuning of new drug candidates
License Out Deal
Reduction in Clinical Trial Costs
Expected Effects of Clinical Translation Research
Drastically enhance the efficiency and pace of new drug development.In the preclinical phase, diversify and validate drug applications and indications, enabling an effective clinical strategy formulation
01
Enhance the success potential of candidate substancesIf anticipated efficacy is not met during clinical stages, revert to the preclinical stage and pursue reverse translation research, including the development of alternate applications or further indication tests
02
Achieve Global-level License-Out (L/O) based on rigorous scientific verification, high-quality preclinical data, and a clinical strategy that increases the probability of success
03
PRIINT
A precise and swift tumor target discovery platform PRIINT has identified 50 new targets solely from pancreatic and ovarian cancer indications
Characteristics of PRIINT
01Creation of an orthotopic model tailored for specific tumors
02Discovery and validation of tumor targets
03Cross-validation of tumor targets using both tumor tissues and blood
Benefits of PRIINT
01Narrow the gap existing between preclinical and clinical stages
02Diminish both the costs and timeline associated with novel drug development
03Ensure cost-effective progression by leveraging existing clinical products